Globe Newswire (Mon, 5-Oct 7:00 AM ET)
BioCryst to Present at Upcoming Investor Conference
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan
Globe Newswire (Tue, 25-Aug 7:01 AM ET)
Market Chameleon (Wed, 5-Aug 3:37 AM ET)
BioCryst Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
BioCryst to Report Second Quarter 2026 Financial Results on August 5
Globe Newswire (Wed, 22-Jul 7:00 AM ET)
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
Globe Newswire (Wed, 15-Jul 7:00 AM ET)
BioCryst Pipeline Focus Shifts: External Innovation Takes the Lead as Internal Discovery Winds Down
Market Chameleon (Mon, 29-Jun 3:29 AM ET)
Market Chameleon (Thu, 26-Feb 2:43 AM ET)
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Biocryst Pharmaceuticals trades on the NASDAQ stock market under the symbol BCRX.
As of October 8, 2026, BCRX stock price declined to $8.29 with 3,801,795 million shares trading.
BCRX has a beta of 0.33, meaning it tends to be less sensitive to market movements. BCRX has a correlation of 0.01 to the broad based SPY ETF.
BCRX has a market cap of $2.12 billion. This is considered a Mid Cap stock.
Last quarter Biocryst Pharmaceuticals reported $218 million in Revenue and $.30 earnings per share. This beat revenue expectation by $30 million and exceeded earnings estimates by $.08.
In the last 3 years, BCRX traded as high as $11.31 and as low as $4.03.
The top ETF exchange traded funds that BCRX belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
BCRX has outperformed the market in the last year with a return of +19.3%, while the SPY ETF gained +16.8%. However, in the most recent history, BCRX shares have underperformed the stock market with its stock returning -24.6% in the last 3 month period and -3.3% for the last 2 week period, while SPY has returned +3.8% and +0.8%, respectively.
BCRX support price is $8.16 and resistance is $8.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCRX shares will trade within this expected range on the day.